- AAIC: Lilly's solanezumab delays Alzheimer's progression by 34%
- Stockwatch: Oscillating fortunes
- Gantenerumab fails; time for Roche to cut its Alzheimer's losses?
- Lilly investing in future, staying out of biotech 'bubble'
- ICAAC 2015: Scrip Connects With Cidara, MerLion And Paratek
- 10 Questions For A Big Pharma Data Captain